Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

Study of Self or Clinic Administration of DepoProvera

NCT01019369
completedphase_2

Estrogen, HDL, and Coronary Heart Disease in Women

NCT00083824
terminatedphase_4

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

NCT01776203
completedphase_4

DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding

NCT01148420

Clinical Trials (4)

Showing 4 of 4 trials
NCT01019369Not Applicable

Study of Self or Clinic Administration of DepoProvera

Completed
NCT00083824Phase 2

Estrogen, HDL, and Coronary Heart Disease in Women

Completed
NCT01776203Phase 4

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

Terminated
NCT01148420Phase 4

DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4